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Abstract: To meet the current need for skeletal tumor-load estimation in prostate cancer (mCRPC), 
we developed a novel approach, based on adaptive bone segmentation. In this study, we 
compared the program output with existing estimates and with the radiological outcome. 
Seventy-six whole-body 99mTc-DPD-SPECT/CT from mCRPC patients were analyzed. The software 
identified the whole skeletal volume (SVol) and classified it voxels metastases (MVol) or normal bone 
(BVol). SVol was compared with the estimation of a commercial software. MVol was compared with 
manual assessment and with PSA-level. Counts/voxel were extracted from MVol and BVol. After six 
cycles of 223RaCl2-therapy every patient was re-evaluated as progressing (PD), stabilized (SD) or 
responsive (PR). SVol correlated with the one of the commercial software (R=0,99, p<0,001). MVol 
correlated with manually-counted lesions (R=0,61, p<0,001) and PSA (R=0,46, p<0.01). PD had a 
lower counts/voxel in MVol than PR/SD (715±190 Vs. 975±215 and 1058±255, p<0,05 and p<0,01) and 
in BVol (PD 275±60, PR 515±188 and SD 528±162 counts/voxel, p<0,001). Segmentation-based tumor 
load correlated with radiological/laboratory indices. Uptake was linked with the clinical outcome, 
suggesting that metastases in PD patients have a lower affinity for bone-seeking radionuclides and 
might benefit less from bone-targeted radioisotope therapies. 
Keywords: mCRPC; SPECT/CT; Computer-assisted diagnosis; XOFIGO; Therapy response 
assessment 
 
1. Introduction 
Castration-resistant prostate cancer (CRPC) is defined by rising PSA levels under androgen 
blockade and by the eventual diffuse metastatic spread [1-3]. In these patients, skeletal metastases 
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can represent the most relevant prognostic factor, by impairing the static function of the skeleton 
and by reducing the available space for hematopoiesis [4-6]. 
Diffuse skeletal CRPC metastatization, once considered a terminal diagnosis, can today be 
managed by many different approaches, including new-generations taxanes, second-line hormonal 
therapy, and radioisotope treatments [7-12]. As these medications might have varying effectiveness 
and cause different side effects, the choice of therapy sequence requires usually a multidisciplinary 
disease-management. Nevertheless, the most effective sequence of systemic treatments is still a 
matter of discussion and patient-specific components are likely to play a relevant role [13-15]. 
Being able to assess treatment response reliably is a pre-requisite for therapy selection and 
sequencing. Response evaluation may be performed either by analyzing tumor marker blood levels 
or by serial imaging. Serum PSA level is the most used marker, but alkaline phosphatase might also 
be helpful in assessing metastasis-dependent bone turnover [16,17].  
Circulating markers are however dependent on the degree of tumor differentiation and can be 
altered by concomitant therapies [18-20]. On the other hand, evaluating medical imaging, whether 
morphological or radioisotope-based, can be challenging in the presence of a high number of 
metastases or in case of therapy-related changes, such as the “flare” phenomenon [21]. 
Obtaining an automated evaluation of the skeletal tumor burden is one of the greatest current 
unmet clinical need; in recent years, an increasing number of software applications have been 
developed for this purpose [22]. Existing applications are mostly based on automated thresholding 
of a SUV or counts value on PET/CT or bone scans; in this setting, telling apart metastases-related 
uptake from other non-malignant sources of increased bone turnover can be challenging. 
To improve the reliability of metastases detection and to obtain a reliable estimation of tumor 
load, we developed a specific computational tool, based on segmentation analysis. This algorithm 
uses the CT information to identify and segment all hyperdense localizations within the skeletal 
system automatically, to define the overall metastatic bone compartment. In a second step 
information from the co-registered SPECT or PET images can be extracted for this volume. In this 
study, we have tested this approach on a series of CRPC patients and validated the analysis against 
different clinical parameters. 
2. Results 
2.1. Volumetric Assessment and Comparison between Systems 
The estimate of total osseous tissue (SVol, sum of MVol, BVol and CVol) showed a tight concordance 
between our software and the commercial application. Mean global skeletal volume was in fact 
3875±1513 ml and 3881±1499 ml as measured by the commercial software application and by our 
computational program, respectively (R=0,99, p<0,001). Mean counts/voxel were 439±71 and 435±61, 
respectively, with a R correlation index of 0,92 (p<0,001, data not shown). Mean MVol was 362±249 
ml (range 85-1194 ml), corresponding to 27±20% of the total trabecular bone.  
The majority of tumor burden was located within the axial skeleton and in the hipbones (MVol 
335±140 ml); 61 patients (81%) had skeletal localizations within the appendicular long bones (MVol 
32±19 ml). 
2.2. Volume Characteristics 
Mean Hounsfield density was comparable for MVol (590±136) and CVol (531±92) but was 
significantly lower for BVol (251±78, p<0.001). Higher tracer activity was measured within MVol 
(939±279 mean counts/voxel), as compared to BVol (462±196 mean counts/voxel, p<0.001). Activity 
concentration within CVol was even lower (271±106 mean counts/voxel), see Table 1. Mean 
counts/voxel were directly correlated to mean HU, for both MVol (R=0.52, p<0.01) and BVol (R=0.74, 
p<0,001, Figure 1). 
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Figure 1. Correlation between counts/voxel and Hounsfield density as well as between volumes and 
number of metastases. A higher density corresponded to higher mean counts/voxel (top panels). 
Furthermore, a close correlation was observed between the volumetric estimates and the manual 
count of metastatic lesions (bottom panels). 
2.3. Tumor Volume, Number of Lesions and PSA-Level 
The software based semi-automatic lesion identification (MVol) and the manual lesion count 
showed a tight correlation, for the whole skeletal system (R=0,61, p<0,001, Figure 1) and the axial 
segments (R= 0,64, p<0,001), but not for the appendicular ones (R= 0.07, p=0.52). Likewise, the 
number of manually counted lesions correlated with the percent of invasion of the trabecular bone 
by metastases (INV%) within the whole (R=0.68) as well as axial (R=0.69) skeleton, p<0,001, Figure 1. 
Remarkably, PSA level as a marker of tumor load correlated with our measures of bone 
involvement (MVol R=0,46, p<0,01; number of manually counted lesions R=0,67, p<0,001; mean HU 
of MVol R=0,42 p<0,01; mean HU BVol (; R= 0,52 p<0,001 and MVol/BVol ratio (R=0,75, p<0,001).  
Impact of “Superscan” Status 
12 patients (16%) were classified as “superscan”. CRPC patients with a “superscan” had a 
higher mean HU than non-superscan patients in BVol (p<0,001 Figure 2) as well as in MVol (p<0,01, 
Figure 2).  
Mean counts/voxel in MVol were higher in superscan subjects than in non-superscan (1104±291 
Vs. 886±251, p<0,05, Figure 2); conversely, mean counts/voxel in BVol were not significantly different 
between the two subpopulations. 
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Figure 2. Comparison between superscan and non-superscan patients. Superscan subjects showed a 
higher density, in BVol as well as in MVol (upper panels). A higher counting rate was observed in the 
MVol of superscan patients (bottom left). Finally, percent of trabecular bone space invaded by 
metastatic lesions was higher in the superscan subjects (bottom right). *p<0.05, **p<0.01, ***p<0.001. 
INV% Percent of bone invaded by metastases (MVol/ BVol). 
Finally, superscan was associated with a higher INV% of trabecular bone by osteoblastic 
lesions (MVol/BVol ratio: 40±23% vs. 21±16%, p<0,01, Figure 5), which was reflected, at qualitative 
analysis, by a higher number of visually observable metastases (N= 106±22 vs. 61±23, p<0,001). 
See Table 1 for a detailed analysis. 
Table 1. Radiological and laboratory parameters in patients with or without superscan. 
Parameter All Patients Superscan Non-Superscan p-value 
Mean MVol (ml) 357±257 527±304 245±187 <0.001 
Number of counted lesions 74±30 106±22 61±23 <0.001 
INV% 27±20% 40±23% 21±16% <0.01 
PSA (ng/ml) 539±754 1235±959 257±407 <0.001 
Mean Counts/Voxel (BVol)  466±198 565±243 428±164 NS 
Mean Counts/Voxel (MVol) 947±277 1104±291 886±251 <0.05 
Mean HU (BVol) 251±78 319±78 223±59 <0.01 
Mean HU (MVol) 590±136 693±132 549±115 <0.001 
2.4. Therapy Response Assessment 
According to the response assessment criteria, which are further detailed in the Material and 
Methods, 21 patients (28%) were classified as PD, while 35 subjects (46%) showed a SD and 20 
patients (26%) showed a PR.   
Patients which presented a PD status after the therapy completion exhibited a markedly lower 
activity in the MVol (715±190 counts) in the pre-therapy scan, when compared to those with PR 
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(N=20, 975±215 counts, p<0,05) or SD (N= 35, 1058±255 counts, p<0,01). Of note, similar findings 
were found within BVol, where patients with PD displayed the lowest activity (PD 275±60, PR 
515±188 and SD 528±162 counts, p<0,001). See Figure 3. 
 
Figure 3. Radioactivity concentration according to response. Patients with “progressive disease” 
after the radioisotope therapy displayed a significantly lower radioactivity concentration at the 
baseline imaging, in MVol as well as in BVol. *p<0.05, **p<0.01, ***p<0.001. 
At ROC analysis, both MVol and BVol mean counts/voxel were predictive of therapy effectiveness 
(MVol 0,895 and BVol 0,943 for, p<0,001). The best threshold value of mean counts/voxel for 
discriminating patients with progressive disease was in fact 805 in the MVol (sensitivity 84%, 
specificity 81%) and 385 in the BVol (sensitivity 84%, specificity 100%). No differences were observed 
in absolute volume of metastases (MVol) across the therapy outcome groups. See Figure 4. 
 
Figure 4. ROC curve of MVol and BVol. counts/voxel according to progression. Radioactivity 
concentration was able to discriminate patients with a progressive disease, in MVol as well as in BVol. 
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Patients presenting a “superscan” pattern of radioactivity distribution were evenly distributed 
among the three groups (PD: 3/21 or 14%, SD 6/35 or 17% and PR 3/20 15%, p=ns). 
PSA level showed considerable variations during the therapy. On average, starting from 
staging to the end of the therapy, it increased by 135±99% in PD patients and by 27±81% in PR 
subjects. Conversely, PSA decreased by 40±16% in SD patients. However, due to the marked spread 
of the PSA-level course among patients, no statistically significant difference could be demonstrated 
among these groups. 
See Table 2 for a detailed analysis. 
Table 2. Radiological and laboratory parameters according to response. 
Parameter PD SD PR PD VS. PR PD VS. SD PR VS. SD 
MEAN MVol (ml) 245±312 342±203 373±254 NS NS NS 
Number of counted 
lesions 56±25 80±33 79±26 NS NS NS 
INV% 19±8% 29±17% 31±23 NS NS NS 
PSA (ng/ml) 353±540 446±539 746±1004 NS NS NS 
Mean Counts/Voxel 
(BVol)  275±60 528±162 515±188 <0.001 <0.001 NS 
Mean Counts/Voxel 
(MVol) 
715±190 1058±255 975±219 <0.05 <0.01 NS 
Mean HU (BVol) 232±81 253±68 264±82 NS NS NS 
Mean HU (MVol) 545±157 605±120 610±127 NS NS NS 
3. Discussion 
The present paper describes a computational approach to the problem of skeletal tumor 
burden quantification by means of SPECT/CT data. The robustness of the bone recognition was 
testified by the tight correlation between the total bone volume as detected by our approach and by 
a commercial application. The automated identification of bone tumor volume could not be 
compared with a reference standard, as, to the best of our knowledge, a commercially available 
CT-based tumor burden estimator does not yet exist. However, the estimates provided by this 
software tool show a tight concordance with the traditional measures of tumor burden performed 
with imaging and blood test. 
In our analysis, we considered both the raw figure of tumor volume as well as the “percent of 
invasion”, i.e. the ratio between tumor and trabecular volume. Both estimators strongly correlated 
with the number of manually counted lesions as well as with the PSA value. 
As expected, patients with a “superscan” status at planar bone scans presented a higher tumor 
volume as well as a higher percent of trabecular bone invaded by bone metastases. These patients 
presented also a higher bone metastases density and counting rate; however, mean counts in 
trabecular bone did not significantly differ from those in the trabecular bone of non-superscan 
patients.  
However, the distribution of radioactivity into the metastases, as well as into the trabecular 
bone, appears to play an important role in the therapeutic effectiveness of 223RaCl2.  Previous 
studies have in fact shown that the distribution of the bone scan tracers mirrors that of 223RaCl2 
[23,24]. In our population, patients who were found to have a disease progression at the end of the 
therapy presented a lower counting rate at the baseline SPECT/CT not only within the known 
tumor lesions, but also in the trabecular bone. It might be hypothesized that a lower counting rate 
at SPECT/CT could correspond to a lesser 223RaCl2 avidity and thus to a reduced absorbed dose. 
Thus, one might hypothesize that micrometastases (if present) in trabecular bone exhibiting only 
low counting rate will receive insufficient therapeutic dose. It is worth noting that tumor volume 
was conversely not significantly different across patients with partial response, stable or 
progressive disease. As a consequence, semi-quantitative evaluation of bone tracer uptake at 
baseline might be useful for 223RaCl2 therapy stratification. 
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Patients presenting with a “superscan” finding were equally distributed in the three response 
groups, i.e. the presence of a “superscan” was per se not associated with imaging-based therapy 
response in our population. Actually, the role of this imaging feature in predicting therapy response 
in patients treated with 223RaCl2 has not been extensively studied. A previous report demonstrated a 
trend for shorter survival in those patients when compared to those with less than 6 metastases [25]; 
however, the relative low frequency of this condition does not allow to reach definite conclusion, 
unless large-scale studies are planned. Nonetheless, our data might suggest that some superscan 
patients might indeed benefit from a 223RaCl2 treatment.  
The robustness of the generated volumetric data and the clinical relevance of the information 
that has been derived from this analysis suggest a relevant potential for the computer-enhanced 
evaluation of tumor burden. The relevance of such approaches is testified by the growing number 
of computer-assisted techniques, which have been developed in the last decades to estimate the 
tumor burden [22]. Different approaches have been presented e.g. the bone-scan index, which is 
designed to be applied to planar bone scintigraphy [26], but was subject to false-positive findings in 
the event of a “flare” phenomenon [27]. Moreover, new 3D-segmentation algorithms have been 
introduced for PET/CT, one based on a 18F-NaF PET-threshold but requiring specific threshold 
determination for each individual scanner [28], the other using the tracer uptake of 68Ga-PSMA [29], 
that might be of special interest for upcoming but currently not approved PSMA radio-ligand 
therapies. The main difference of our approach lies on the use of CT-density contrast instead of the 
PET information for defining tumor volume as well as the applicability to any CT-based hybrid 
imaging PET/CT and SPECT/CT, the latter being more widespread available and less cost intensive. 
A major advantage of our current approach with SPECT/CT relies on Finally, the use of bone 
seeking tracers might better reflect the uptake of 223RaCl2 and thus predict the radiation to the 
metastases. one algorithm included a segmentation.  
Some limitations have to be mentioned. A possible source of error could be a misclassification 
of non-tumor-related bone thickening [30]. The application automatically excludes non-bone 
hyperdensity (e.g., vascular calcification) from the edge detection. Likewise, voxel belonging to the 
spinal canal and hypodense areas (such as bone cysts) are also sorted out. Our approach was shown 
to be congruent with the estimation of bone volume as provided by a standard commercial 
software. However, a comparison to an independent imaging-based reference standard provided 
by means of MR or PSMA-PET/CT was not available. Moreover, comparison with other approved 
methods of tumor load determination, based on planar data, such as the bone scan index [31], was 
not possible because of their intrinsic difference.  
 Another significant limitation is that, in the SPECT/CT analysis, the limited resolution of the 
single-photon technique could underestimate the counts in smaller volumes. Finally, we evaluated 
the therapy response only in subject that completed the entire 223RaCl2 therapy. This decision was 
made in order to have a homogenous population and to be able to perform a therapy effectiveness 
evaluation at the same time point after baseline staging. However, this choice excluded patients 
which have interrupted the therapy due to tumor-progress or because of toxicity; therefore, the 
information presented in this manuscript apply only to the patient population with a relatively 
better prognosis[32]. Further studies could shed light on the correlation among tumor load, tracer 
distribution and overall survival in patients with in-therapy progression. 
4. Materials and Methods  
4.1. Patients’ Population 
Seventy-six consecutive patients suffering from CRPC, who underwent whole-body 
99mTc-bisphosphonate-SPECT/CT (mean age 69.5±7, age range 55.5-80.8), were retrospectively 
analyzed. All examinations had been performed for staging in patients with multiple bone lesions, 
before radionuclide therapy using 223RaCl2. Inclusion criteria comprised histologically confirmed 
prostate cancer, evidence of prostate specific antigen (PSA) increase under maximal androgen 
blockade and presence of clinically symptomatic as well as radiologically confirmed osteoblastic 
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skeletal metastases. Exclusion criteria were presence of metal implants impeding the analysis of 
either the axial or the appendicular skeleton (e.g. bilateral total hip replacement; extensive 
spondylosyndesis etc.), absence of a signed informed consent and inability to complete the planned 
six-cycles 223RaCl2-therapy. Any previous therapy or combination of treatments was admitted. PSA 
level at the time of scan was recorded. 
All patients gave written informed consent for the retrospective analysis of the 
pseudonymized clinical SPECT/CT data. The investigations were conducted in accordance with the 
Helsinki Declaration and with national regulations, after approval by the ethics committee of the 
University of Tübingen. All patients had signed a specific consent form, detailing the use of 
imaging as well as of laboratory data for research purpose. 
4.2. Patients’ Follow Up 
Patients were followed up throughout the execution of the radionuclide therapy, which 
included six 223RaCl2 administrations (one per month). A whole-body SPECT/CT scan was carried 
out at the end of therapy. This scan was re-evaluated by an experienced viewer, which was blinded 
to the results of the computational analysis, and stratified the patients according to therapy 
response, as follows: if new lesions were detected (whether on CT or in the SPECT images), the case 
was classified as progressive disease (PD). On the contrary, if no new lesions were observed, the 
patient was considered having a stable disease (SD). Finally, if no new lesions were observed and 
the uptake intensity was visibly diminished, the case was judged as partial response (PR). This 
study was approved by Local Ethics Committee of the University of Tübinngen (No. 747/2017BO1) 
on 9 th March 2015. 
4.3. Scan Protocol 
Patients were scanned on a hybrid SPECT/CT device (Discovery 670 Pro, GE Healthcare, 
Chicago, US), three hours after injection of 8-10 MBq/Kg of 99mTc-DPD (CIS bio, Berlin, Germany). 
To minimize artifacts caused by the presence of radioactive urine in the excretory system, patients 
were asked to drink at least 1000 ml of water during the uptake time and to void immediately 
before the scan. No urinary bladder catheterization was used.  
The acquisition protocol comprised a whole-body planar scan. This part was followed by a 
whole-body SPECT/CT scan, from vertex up to mid-distal femur, which was obtained by 
reconstructing and fusing three sequential fields-of-view on a dedicated workstation (Xeleris 3®, 
GE Healthcare, Chicago, US). SPECT acquisition was carried out with the two cameras heads in 
H-Mode; parameters for each field-of-view were as follows: energy window 140.5±10%, angular 
step 6°, time per step 15’’. The transaxial field of view and pixel size of the reconstructed SPECT 
images were 54cm and 5x5 mm, respectively, with a matrix size of 128 × 128. SPECT raw data were 
reconstructed using OSEM iterative protocol (2 iterations, 10 subsets). 
The technical parameters of the 16-detector row, helical CT scanner included a gantry rotation 
speed of 0.8 s and a table speed of 20 mm per gantry rotation. The scan was performed at 120 kV 
voltage and 10-80 mA current. A dose modulation system (OptiDose®, GE Healthcare, Chicago, 
US) was applied to optimize total exposure according to the patient’s body size. No contrast 
medium was injected. 
4.4. Image Analysis 
Segmentation of bone volumes was performed on the CT data according to the previously 
validated method [33-35]. Briefly, the algorithm identified the skeleton on CT images by assuming 
that compact bone is the structure with the highest X-ray attenuation coefficient in the human body. 
This assumption implies a stark HU values difference between soft tissue and cortical bone. The 
program functions by reading the HU values of every voxel in any given slice horizontally; when it 
encounters a sharp variation of HU density, it assumes that it had reached the bone outer border. 
From that point, it samples a 2-pixel ring, which corresponds to the cortical bone. It then samples 
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the average density of this cortical bone volume. Thereafter, it categorizes every voxel on the inside 
of this volume as trabecular bone (bone volume, BVol) or as osteoblastic metastases volume (MVol). 
This is done by using the mean density of the cortical volume as cutoff value, assuming the 
osteoblastic metastases will have an average density at least equal to the one of cortical bone. 
Therefore, the final output of this process consists of the following volumes: - Cortical Volume (CVol): the bone surface - Trabecular Volume (BVol): the normal trabecular bone - Metastases Volume (MVol): osteoblastic metastases (tumor burden) - Skeletal Volume (SVol): entire skeletal volume (sum of CVol, BVol and MVol)  - %INV: percent of invasion (MVol/ BVol ratio) 
A graphical overview of the segmentation process and an example of the program’s working 
on the original slices are shown in Figure 5 and in Figure 6. 
 
Figure 5. Functioning of the segmentation process. The software analyzes sequentially the HU 
density of voxel within a single slice (top left). The bone border is identified as an increase of HU 
values (top center). After definition of the cortical volume (CVol, top right), its mean HU density is 
calculated. This value is used to classify all voxels located on the inside of CVol as pertinent to bone 
metastases (MVol) or to normal trabecular bone (BVol, middle and left bottom panels). Afterwards, 
mean counts/voxel are extracted from the co-registered images (bottom right). 
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Figure 6. Examples of the segmentation output. 3D MIP representations (top panels) and transaxial 
views (bottom panles) of the original images (left) and of the processed DICOM outputs (center and 
right). 
For details on the mathematical rationale underlying the bone recognition algorithm, please 
see the original work from Sambuceti et al. [33]. For an overview on the principle of tumor burden 
estimation, we refer to our previous work [6]. 
After an initial automatic segmentation, the program displayed the resulting images to the 
operator, which could manually exclude all benign hyperdensities (e.g. osteochondrosis, 
osteophytes, metal implants). Purely lytic areas, having a HU inferior to 30, were automatically 
removed).  
In the next step, masks corresponding to the MVol and the BVol were generated and exported 
onto the co-registered SPECT images; here, mean radioactivity concentration (counts/voxel) was 
calculated. The program’s output included the volume (in ml), the mean HU density and the mean 
counts of both volumes MVol and BVol. For the purpose of the present study, the skull was excluded 
from the analysis. Separate computations were then conducted for the whole-body (the whole 
skeleton from atlas until the distal femurs), the axial skeleton (vertebrae and sternum) and the 
appendicular bones (humeral and femoral shafts).  
4.5. Validation of the Computational Technique and Comparison with Controls 
In order to correlate the information obtained by the new program with known indices, we 
compared the magnitude of volumes, density values and tracer distribution with approved 
radiological, clinical and laboratory standards of reference. In the first step, we aimed to verify the 
correctness of the bone identification by our program. To do so, we compared the total SVol with a 
volumetric estimate of the whole skeleton, obtained by a licensed commercial application 
(QMetrix®, General Electric, Boston, MA, US). This comparison was done to ensure that our 
method could correctly recognize the bone volume on the CT images.  
In the second step, we compared the MVol (as an estimate of the tumor burden) with the 
absolute number of metastatic lesions, which were manually counted on the SPECT/CT images by 
an expert reader. Finally, MVol, mean MVol HU, average MVol counts and ratio between MVol and BVol 
were correlated to PSA levels.  
To further stratify disease aggressiveness, both HU values and counts of MVol were compared 
between patients with or without a “superscan” finding at planar imaging. Superscan was defined 
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as the presence of uniformly increased activity within the skeleton, with very faint or absent 
visualization of the renal system [36]. 
4.6. Statistical Analysis 
Data are presented as mean ±standard deviation. T-Test for unpaired data was used to 
compare values between patients’ subgroups. To verify the probability of therapy response in 
function of the measured counts within the segmented volumes ROC-analyses were performed, 
and AUC-values calculated. Correlation between indexes was assessed with bivariate analysis, 
using Pearson’s R index. Prevalence of “superscan” patients among groups was tested using 
Chi-squared test. 
A P-value of <0.05 was considered significant. The SPSS statistical program (SPSS®, v. 21.0, 
IBM, Armonk NY, USA) was employed.  
5. Conclusions 
This study aimed to contribute to the transition to the tailored treatment in the field of 
metastasized castration-resistant prostate cancer. The availability of reliable indices of disease 
burden and the capability to measure therapy response accurately, as well to predict its clinical 
course, are key in ensuring the best possible treatment to every single patient. The present paper 
presents a method by which disease-specific indices, mirroring the corresponding parameters of 
disease status, can be obtained. The capability to extract this data can potentially be used, pending 
further studies, to ameliorate the imaging-based disease stratification and to improve the 
therapeutic schedule, therefore improving treatment effectiveness in these patients. 
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